This is an observer-blinded, comparative, single dose, clinical phase II/III study to assess the immunogenicity and safety of EuTCV compared to Typhoid conjugate vaccine in healthy Filipino participants aged 6 months to 45 years.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Enrollment
444
Single dose, Intramuscular administration
Single dose, Intramuscular administration
De La Salle Medical and Health Sciences Institute
Cavite, Philippines
University of the East Ramon Magsaysay Memorial Medical Center
Quezon City, Philippines
Seroconversion rate
Time frame: 4 weeks after vaccination of EuTCV (pooled of 3 batches)/Typbar-TCV compared to baseline
Proportion of Solicited local and systemic AEs
Time frame: 7 days after vaccination
Proportion of unsolicited AEs
Time frame: within 28 days after vaccination
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.